Edgewise Therapeutics, Inc.
For the period ended Jun 4, 2026. Filed Apr 23, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 4, 2026 · Filed Apr 23, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
(Amendment No. )
| Filed by the Registrant ⌧Filed by a party other than the Registrant ☐ | |
|---|
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |
EDGEWISE THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
| Payment of Filing Fee (Check the appropriate box): | ||
|---|---|---|
| ⌧ | No fee required. | |
| ☐ | Fee paid previously with preliminary materials. | |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. | |
| | | |
| | | |
About Us
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe muscle diseases for which there is significant unmet medical need. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combined our foundational expertise in muscle biology and small molecule engineering to build our proprietary, muscle-focused drug discovery platform. Our platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. We have developed and characterized a library of novel sarcomere modulators exhibiting a broad range of pharmacological and pharmacokinetic properties regulating disease-related muscle biology.
| | | |
|---|---|---|
| | PATIENTS FIRST | |
| Our goal is to understand the challenges individuals living with the diseases we work in, their families and their caregivers face every day to help us develop meaningful treatments. By doing this we can better serve the communities we serve and improve all aspects of our work to develop impactful and potentially life-changing treatments.Our Guiding Principles●Start with patients. Consider the voice of the patient at every step of the way.●Create and follow the science to lead us to novel therapies.●Work with uncompromising standards and integrity.●Communicate honestly, openly and compliantly.●Meet the challenge with urgency. |
i
| | | |
|---|---|---|
| | OUR VISION | |
| Our vision is to improve the lives of patients and families suffering from severe muscle diseases by building the world’s leading muscle-focused biopharmaceutical company. Key components of our strategy to achieve this vision include:●Engaging comprehensively with patients, their families and their physicians to develop trusted relationships, transparent communications, and become a leader in the rare muscle disease communities we serve; ●Leveraging clinical and regulatory precedents and our extensive experience in severe muscle diseases to rapidly advance sevasemten through clinical development in muscular dystrophies;●Leveraging our deep expertise in muscle-disease therapeutics to expand our pipeline, advancing EDG-7500 through clinical development for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction;●Investing in our precision medicine drug discovery platform to fuel the development of novel targeted therapies to expand our pipeline into additional skeletal and cardiac muscle diseases;●Integrating our scientific expertise, development capabilities and growing network of patient advocacy groups and collaborators to develop novel therapies addressing muscle diseases with the highest unmet need; and●Opportunistically evaluating strategic collaborations and asset acquisition opportunities to accelerate development and commercialization timelines as well as potentially expanding our pipeline within our core therapeutic areas. |
ii
Notice of Annual Meeting of Stockholders
| | | | ||
|---|---|---|---|---|
| DATE AND TIME | | IN-PERSON MEETING | | RECORD DATE |
| June 4, 2026 at 10:00 am Mountain Time | | This year’s annual meeting of stockholders (Annual Meeting) will be held in-person at: 1715 38th Street, Boulder, Colorado 80301 | | April 9, 2026 |
| ITEMS OF BUSINESS | | BOARD VOTINGRECOMMENDATION |
|---|---|---|
| Proposal No. 1: Elect the directors named in the attached Proxy Statement to serve until the 2029 annual meeting of stockholders | FOR the election of Laura Brege, Badreddin Edris, Ph.D. and Jonathan Root, M.D. | |
| Proposal No. 2: Ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 | | FOR the ratification of KPMG LLP |
| Proposal No. 3: Conduct an advisory vote on the compensation of our named executive officers | FOR the approval, on an advisory and non-binding basis, of the compensation of our named executive officers |
Stockholders will also consider such other business as may come properly be presented before the Annual Meeting or any adjournment thereof.
This notice, proxy statement and voting instructions are being mailed to stockholders on or about April 23, 2026.
iii
YOUR VOTE IS IMPORTANT
Regardless of whether you plan to attend the live in-person meeting, we encourage you to vote as soon as possible in one of the following ways:
| | | | ||||
| VIA THE INTERNET | BY TELEPHONE | BY MAIL | AT THE IN-PERSON MEETING | |||
|---|---|---|---|---|---|---|
| Visit the website listed on your proxy card | Call the telephone number on your proxy card | Sign, date, and return your proxy card in the enclosed envelope | Attend the Annual Meeting at 1715 38th Street, Boulder, Colorado 80301 |
John R. Moore
General Counsel
Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 4, 2026. Our Proxy Statement and Annual Report are available online at investors.edgewisetx.com.
iv
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.